| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $3.93B | -3.0% |
| Cost of Revenue | $2.78B | -0.6% |
| R&D Expense | $169.3M | -5.4% |
| SG&A Expense | $392.2M | +11.8% |
| Operating Income | $149.3M | -17.8% |
| Interest Expense | $155.8M | -14.5% |
| Pre-tax Income | -$11.8M | -166.3% |
| Income Tax | -$140.3M | -745.1% |
| Net Income | $128.5M |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $593.7M | +16.8% |
| Accounts Receivable | $660.2M | -11.3% |
| Inventory | $614.5M | -13.9% |
| Current Assets | $2.03B | -3.6% |
| Total Assets | $7.14B | -7.0% |
| Current Liabilities | $711.4M | -13.6% |
| Long-term Debt | $3.20B | -5.9% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $551.5M | +20.8% |
| Investing Cash Flow | -$19.2M | +88.4% |
| Financing Cash Flow | -$442.8M | +56.4% |
| +3386.7% |
| EPS (Basic) | $0.85 | +2933.3% |
| EPS (Diluted) | $0.85 | +2933.3% |
| Total Liabilities |
| $4.25B |
| -9.2% |
| Stockholders' Equity | $2.89B | -3.5% |